| Description | Amelubant (BIIL 284) is a prodrug of active metabolites BIIL 260 and BIIL 315. Anti-inflammatory activity[1]. Amelubant (BIIL 284) is a potent, oral and long acting LTB4 receptor antagonist, negligibly binds to LTB4 receptor, with Kis of 221 nM and 230 nM in vital cells and membranes. |
| In vitro | Amelubant is a prodrug of active metabolites BIIL 260 and BIIL 315. Which are reversible and competitive LTB4 receptor antagonists, with Kis of 1.4, 1.1 nM and 1.7, 1.9 nM in vital cells and membranes, respectively[1]. |
| Target activity | LTB4:221 nM （ki）（ in vital human granulocytes), LTB4:230 nM （ki）（ in cell membranes) |
| Synonyms | BIIL 284 |
| molecular weight | 538.63 |
| Molecular formula | C33H34N2O5 |
| CAS | 346735-24-8 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year |
| References | 1. Birke FW, et al. In vitro and in vivo pharmacological characterization of BIIL 284, a novel and potent leukotriene B(4) receptor antagonist. J Pharmacol Exp Ther. 2001 Apr;297(1):458-66. |